Myopia Control: a Comparison Study Between Atropine and MiSight

Inclusion Criteria: Children age of 5-12 years old at their baseline exam Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia) Gestational age ≥ 32 weeks. Birth weight >1500g. Exclusion Criteria: Current or previous form of myopia control Current or previous use of bifocal, progressive- addition lenses, or multifocal contact lenses Known atropine allergy or contact lens intolerance (allergy to only one can still allow enrollment in the other group) Abnormality of cornea, lens, central retina, iris, or ciliary body Current or prior history of manifest strabismus, amblyopia, or nystagmus Current or previous myopia treatment with atropine, pirenzepine or another anti-muscarinic agent. Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses. Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression. Abnormality of the cornea, lens, central retina, iris, or ciliary body. Prior eyelid, strabismus, intraocular, or refractive surgery. Down syndrome or cerebral palsy. Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease) Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence refractive development Any condition that in the judgement of the investigator could potentially influence refractive development. Existing conditions that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, diabetes mellitus, pre-diabetes) Inability to comprehend and/or perform any study-related clinical tests